AHA Scientific Sessions 2026 Abstract
Exenatide lowered protein-based age scores in people
Over 12 months, exenatide lowered six organ-related age scores and limited a liver score’s rise compared with placebo in people with type 2 diabetes.Over 12 months, exenatide lowered six organ-related age scores and limited a liver score’s rise compared with placebo in people with type 2 diabetes.
Randomized trial · 3,973 peopleExenatide
Who was studied3,973 people with type 2 diabetes, 12 months, against placebo
What changedExenatide lowered six organ-related age scores and limited a liver score’s rise compared with placebo
The catchOnly participants with blood samples at both time points were included